Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | TP53 | P04637 | 9/20 | 0.66 |
| ▸ | MAPT | P10636 | 8/20 | 0.66 |
| ▸ | POLB | P06746 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896230 | 0.86 | TP53 (0.73) | LMNATP53MAPTPOLBALDH1A1 | |
| SCHEMBL16896033 | 0.85 | LMNA (0.70) | LMNATP53MAPTPOLBALDH1A1 | |
| SCHEMBL16903565 | 0.85 | MAPT (0.80) | LMNATP53MAPT | |
| SCHEMBL16896188 | 0.84 | POLB (0.76) | LMNATP53MAPTPOLBALDH1A1 | |
| SCHEMBL16896197 | 0.83 | LMNA (0.68) | LMNATP53MAPTPOLBALDH1A1 | |
| SCHEMBL16896201 | 0.83 | TP53 (0.69) | LMNATP53MAPTPOLBALDH1A1 | |
| SCHEMBL16896220 | 0.83 | TP53 (0.68) | LMNATP53MAPTPOLBALDH1A1 | |
| SCHEMBL20096187 | 0.82 | ALDH1A1 (0.85) | LMNATP53MAPTPOLBALDH1A1 | |
| SCHEMBL16896113 | 0.82 | LMNA (0.68) | LMNATP53MAPTPOLB | |
| SCHEMBL16896231 | 0.82 | POLB (0.68) | LMNATP53MAPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180110784-A1 | SYNTHETIC TLR4 AND TLR7 LIGANDS TO PREVENT, INHIBIT OR TREAT LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-26 | — | — | US | disclosed |
| US-20180110784-A1 | SYNTHETIC TLR4 AND TLR7 LIGANDS TO PREVENT, INHIBIT OR TREAT LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110784-A1 | SYNTHETIC TLR4 AND TLR7 LIGANDS TO PREVENT, INHIBIT OR TREAT LIVER DISEASE | TLR4, TLR9, TLR1 | LMNA 1948/4885TP53 2145/4885MAPT 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.